 Bone pain is the major manifestation of skeletal metastases. Although various treatment modalities are available for bone pain palliation , use of radiolabeled phosphonates is documented to be more effective. Among radionuclides available for this purpose , lutetium-177 is gaining popularity due to its moderate beta energy , theranostic capability , favorable half-life and convenient production logistics.